Sun Cheng-Peng, Zhang Xin-Yue, Morisseau Christophe, Hwang Sung Hee, Zhang Zhan-Jun, Hammock Bruce D, Ma Xiao-Chi
Dalian Key Laboratory of Metabolic Target Characterization and Traditional Chinese Medicine Intervention, College (Institute) of Integrative Medicine, College of Pharmacy, Dalian Medical University, Dalian 116044, People's Republic of China.
Department of Entomology and Nematology, UC Davis Comprehensive Cancer Center, University of California, Davis, California 95616, United States.
J Med Chem. 2021 Jan 14;64(1):184-215. doi: 10.1021/acs.jmedchem.0c01507. Epub 2020 Dec 28.
Soluble epoxide hydrolase (sEH) is an α/β hydrolase fold protein and widely distributed in numerous organs including the liver, kidney, and brain. The inhibition of sEH can effectively maintain endogenous epoxyeicosatrienoic acids (EETs) levels and reduce dihydroxyeicosatrienoic acids (DHETs) levels, resulting in therapeutic potentials for cardiovascular, central nervous system, and metabolic diseases. Therefore, since the beginning of this century, the development of sEH inhibitors is a hot research topic. A variety of potent sEH inhibitors have been developed by chemical synthesis or isolated from natural sources. In this review, we mainly summarized the interconnected aspects of sEH with cardiovascular, central nervous system, and metabolic diseases and then focus on representative inhibitors, which would provide some useful guidance for the future development of potential sEH inhibitors.
可溶性环氧化物水解酶(sEH)是一种α/β水解酶折叠蛋白,广泛分布于包括肝脏、肾脏和大脑在内的众多器官中。抑制sEH可有效维持内源性环氧二十碳三烯酸(EETs)水平并降低二羟二十碳三烯酸(DHETs)水平,从而产生对心血管、中枢神经系统和代谢疾病的治疗潜力。因此,自本世纪初以来,sEH抑制剂的开发一直是一个热门研究课题。通过化学合成或从天然来源分离出了多种有效的sEH抑制剂。在本综述中,我们主要总结了sEH与心血管、中枢神经系统和代谢疾病的相互关联方面,然后重点介绍了代表性抑制剂,这将为潜在sEH抑制剂的未来开发提供一些有用的指导。